Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilobelimab in Pyoderma Gangrenosum (OPTIMA)
NCT03971643Phase 2Completed
- Sponsor
- InflaRx
- Start
- May 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of vilobelimab in pyoderma gangrenosum (PG), sponsored by InflaRx. Started May 2019; status: completed.
02
Drugs
vilobelimab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT03971643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971643.